Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 176

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 176
---
, reflecting lower net selling prices due to a change in reimbursement channel mix and an inventory adjustment in anticipation of the previously- announced 2024 US list price reduction. In the Rest of the World region, sales were down by 16.9% CER, mainly due to the Value Based Procurement rollout in China. Toujeo net sales were € 1,123 million in 2023, up 6.8% CER. Growth was driven mainly by the Rest of the World region ( +29.1% CER), due to the Value Based Procurement program in China and the associated acceleration in sales volumes. The impact was partly offset by lower sales in the United States ( -23.0% CER) due to price erosion. Net sales of the Fabry disease treatment Fabrazyme in 2023 were € 990 million (+ 11.9% CER), driven by the Rest of the World region (+ 22.0% CER at € 246 million) followed by the United States (+ 9.8% CER at € 503 million). The year-on-year increase reflects more patients adopting the product across all three regions. Net sales of Lovenox were € 1,122 million in 2023 , down 7.8% CER, reflecting strong biosimilar competition across all geographies. Plavix net sales reached € 948 million in 2023 , up 4.5% CER , in line with consistent volume growth in China. Sales of Myozyme/Lumizyme (Pompe disease) were down year-on-year ( -14.8% CER at € 782 million) as patients switched to Nexviazyme. In 2023 , sales of Nexviazyme/Nexviadyme represented 35.2% of total sales for the Pompe disease franchise. Cerezyme sales were up 10.1% CER at € 686 million on a solid performance in the Rest of the World region (+ 29.2% CER at € 268 million), driven by new patients on therapy and favorable pricing. In 2023 , net sales of Alprolix were € 540 million, up 11.3% CER, driven by the United States where sales of the product reached € 440 million, up 11.6% CER. Praluent posted net sales of € 422 milli on, up 15.2% CER